Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2003

View Archived Issues

PDGF-D: a novel target for the treatment of mesangioproliferative glomerulonephritis

TV-3326 attenuates MPTP-induced dopaminergic neurotoxicity in mice

CHF-3381 blocks NMDA receptors in vitro and in vivo

BN-82451 attenuates striatal lesions in a rat model of Huntington's disease

ETA receptor antagonism preserves myocardial perfusion response in hypercholesterolemic pigs

New JNK3 and/or hCK1e inhibitors from fungal origin claimed by Aventis

Roche and Vernalis present novel 5-HT2C agonists for obesity and other uses

Novel LXR modulators discovered by Tularik team

Vicore patent covers new AT2 agonists and their use in dyspepsia, IBS, etc.

King patents adenosine A2B antagonists with utility in asthma and ocular disorders

New antithrombotic serine protease inhibitor patented by former Pharmacia

Nexium intravenous formulation submitted to FDA

DOS-47 demonstrates preclinical antitumor activity

Bicifadine as effective as tramadol in phase III pain study

InNexus and Corixa enter antibody research, development and license agreement

New trial approved to evaluate GTI-2040 in combination with docetaxel for NSCLC

Efficacy of drug for dry mouth in preventing lung cancer claimed in recent patent

New option for patients with lipid disorders introduced in U.S.

Anti-invasins as a novel class of antifungal agent

Merck and Alnylam enter RNAi development collaboration

Valcyte approved for CMV prevention in transplant patients

New multiple-dose trial evaluates R-112 for allergic rhinitis

Panacea expands research agreement with MIT

BresaGen acquires XeriJect drug delivery platform

Fungicidal compound GL-48656 possesses favorable in vivo properties

Acylides synthesized at Taisho to overcome resistance in key respiratory tract pathogen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...